MENU
+Compare
NVO
Stock ticker: NYSE
AS OF
Nov 19, 11:53 AM (EDT)
Price
$48.16
Change
+$0.62 (+1.30%)
Capitalization
216.08B

NVO stock forecast, quote, news & analysis

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world... Show more

NVO
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. NVO showed earnings on November 05, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for NVO with price predictions
Nov 18, 2025

NVO's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for NVO turned positive on November 13, 2025. Looking at past instances where NVO's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NVO's RSI Oscillator exited the oversold zone, of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NVO advanced for three days, in of 337 cases, the price rose further within the following month. The odds of a continued upward trend are .

NVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 71 cases where NVO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on October 15, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NVO as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

NVO moved below its 50-day moving average on October 17, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NVO crossed bearishly below the 50-day moving average on October 22, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for NVO entered a downward trend on November 18, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.000) is normal, around the industry mean (8.823). P/E Ratio (13.106) is within average values for comparable stocks, (24.048). Projected Growth (PEG Ratio) (1.512) is also within normal values, averaging (2.059). Dividend Yield (0.036) settles around the average of (0.027) among similar stocks. P/S Ratio (4.308) is also within normal values, averaging (3.594).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Dividends

NVO paid dividends on August 26, 2025

Novo-Nordisk A/S NVO Stock Dividends
А dividend of $0.58 per share was paid with a record date of August 26, 2025, and an ex-dividend date of August 18, 2025. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 99.74B. The market cap for tickers in the group ranges from 72.83K to 921.91B. LLY holds the highest valuation in this group at 921.91B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -0%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 16%. CHGCF experienced the highest price growth at 17%, while SCLX experienced the biggest fall at -13%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -23%. For the same stocks of the Industry, the average monthly volume growth was 39% and the average quarterly volume growth was 590%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 32
P/E Growth Rating: 60
Price Growth Rating: 49
SMR Rating: 61
Profit Risk Rating: 74
Seasonality Score: 4 (-100 ... +100)
View a ticker or compare two or three
NVO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical products

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
Novo Alle 1
Phone
+45 44448888
Employees
64319
Web
https://www.novonordisk.com